PCSK9 and atherosclerosis: We could not categorize the ASCVD patients in our study as high compared with very high risk, and it is possible that physicians may have not prescribed a PCSK9 inhibitor in a patient who was eligible based on their treated LDL cholesterol level because they felt the patient was not particularly high risk.